Table 2

Clinical findings before after testing positive for COVID-19

Patient	Diagnosis	Age	Gender	Biologic treatment	BMI	Interval between doses (weeks)	Other treatments	Uveitis status				Interval between positive and negative COVID-19 tests	COVID-19 symptoms
Patient	Diagnosis	Age	Gender	Biologic treatment	BMI	Interval between doses (weeks)	Other treatments	Status of uveitis before testing positive for COVID-19	Was biologic treatment postponed?	Status of uveitis after clearance from COVID-19	Was the biologic therapy resumed after clearance from COVID-19	Interval between positive and negative COVID-19 tests	COVID-19 symptoms
1	Behçet	29	Male	Adalimumab	28.2	2	MMF	Quiet	Yes	Active	Yes	4	Asymptomatic
2	Behçet	38	Male	Infliximab	26.5	8	MMF	Quiet	Yes	Active	Yes	5	Asymptomatic
3	Behçet	48	Female	Infliximab	32.7	10	MMF	Quiet	Yes	Quiet	Yes	3	Asymptomatic
4	Behçet	25	Male	Infliximab	22.3	8	MMF	Quiet	Yes	Quiet	Yes	4	Asymptomatic
5	Behçet	35	Male	Infliximab	25.1	6	Oral steroids	Quiet	Yes	Quiet	Yes	6	Asymptomatic
6	Behçet	38	Male	Infliximab	20.7	8	None	Quiet	Yes	Quiet	Yes	3	Asymptomatic
7	Idiopathic intermediate uveitis	28	Female	Infliximab	25.5	6	Cyclosporine	Quiet	Yes	Quiet	Yes	2	Asymptomatic
8	Idiopathic panuveitis	9	Male	Adalimumab	27.6	2	Topical steroids	Quiet	Yes	Quiet	Yes	2	Asymptomatic
9	Diffuse subretinal fibrosis syndrome	25	Male	Rituximab	23	2*	MMF	Quiet	Yes	Quiet	Yes	2	Asymptomatic

*Patient started on rituximab one dose and found to be COVID-19 positive when presented for the second dose.
BMI, body mass index; MMF, mycophenolate mofetil.